Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Predictive Oncology Inc POAI

Healthcare Medical Devices
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples... see more

Recent & Breaking News (NDAQ:POAI)

Predictive Oncology’s Skyline Medical Division Expands Its Asian Market Share with First-Ever Orders of STREAMWAY Systems in India

GlobeNewswire August 6, 2019

Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid Cancer via AI-Driven Models

GlobeNewswire July 30, 2019

Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data and Artificial Intelligence-Driven Approach to Treating Ovarian Cancer

GlobeNewswire July 18, 2019

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

GlobeNewswire July 18, 2019

Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement with ChemImage to Expand Personalized Medicine to Prostate Cancer Prognosis and Treatment

GlobeNewswire June 26, 2019

Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Officer of Helomics

GlobeNewswire June 12, 2019

Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc.

GlobeNewswire June 11, 2019

Precision Therapeutics Gains Extension for Nasdaq Compliance

GlobeNewswire May 17, 2019

Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire May 15, 2019

Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019

GlobeNewswire May 13, 2019

Precision Therapeutics' Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next-Generation Patient Registry for Alopecia Areata Research

GlobeNewswire April 18, 2019

Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine Opportunities for Cancer Patients

GlobeNewswire April 11, 2019

Uptick Newswire Hosts Precision Therapeutics Inc. on The Stock Day Podcast to Discuss Massive Revenue Increases

Accesswire April 11, 2019

Precision Therapeutics’ Subsidiary Helomics to Collaborate with Viome to Explore the Impact of the Gut Microbiome on Ovarian Cancer

GlobeNewswire April 9, 2019

Precision Therapeutics Announces Completion of Merger with Helomics Holding Corporation

GlobeNewswire April 5, 2019

Precision Therapeutics Reports Year End 2018 Financial Results and Provides Corporate Update

GlobeNewswire April 1, 2019

Dawson James Securities Announces the Closing of Public Offering for Precision Therapeutics Inc.

GlobeNewswire April 1, 2019

Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.2 Million of Units

GlobeNewswire March 27, 2019

Precision Therapeutics Inc. Announces Proposed Public Offering of Securities

GlobeNewswire March 26, 2019

Precision Therapeutics Announces Results of Special Meeting of Stockholders

GlobeNewswire March 25, 2019